SOCS1 Inhibits IL-6-Induced CD155 Overexpression in Lung Adenocarcinoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 27

PMID 39596207

Authors

Mario Marroquin-Mucino

Jesus J Benito-Lopez

Mario Perez-Medina

Dolores Aguilar-Cazares

Miriam Galicia-Velasco

Rodolfo Chavez-Dominguez

Sergio E Meza-Toledo

Manuel Meneses-Flores

Angel Camarena

Jose S Lopez-Gonzalez

Affiliations

Soon will be listed here.

Abstract

CD155, also known as the poliovirus receptor (PVR), is a crucial molecule in the development and progression of cancer, as its overexpression favors immune evasion and resistance to immunotherapy. However, little is known about the mechanisms that regulate its overexpression. Proinflammatory factors produced by various cellular components of the tumor microenvironment (TME) have been associated with CD155 expression. We analyzed the effect of interleukin (IL)-6 on CD155 expression in lung adenocarcinoma. We found a positive relationship between mRNA and protein levels. This correlation was also observed in bioinformatics analysis and in biopsies and serum from patients with lung adenocarcinoma. Interestingly, lung adenocarcinoma cell lines expressing suppressor of cytokine signaling 1 (SOCS1) did not show increased CD155 levels upon IL-6 stimulation, and SOCS1 silencing reverted this effect. IL-6 and SOCS1 are critical regulators of CD155 expression in lung adenocarcinoma. Further basic and clinical studies are needed to define the role of these molecules during tumor development and to improve their clinical impact as biomarkers and targets for predicting the efficacy of immunotherapies. This study deepens the understanding of the intricate regulation of the immune checkpoints mediated by soluble factors and allows us to devise new ways to combine conventional treatments with the most innovative anticancer options.

References

Samanta D, Almo S . Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci. 2014; 72(4):645-58. PMC: 11113404. DOI: 10.1007/s00018-014-1763-4. View

Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A . SOCS, inflammation, and cancer. JAKSTAT. 2013; 2(3):e24053. PMC: 3772102. DOI: 10.4161/jkst.24053. View

Muller S, Mayer S, Moller P, Barth T, Marienfeld R . Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma. Neoplasia. 2021; 23(6):584-593. PMC: 8190489. DOI: 10.1016/j.neo.2021.05.005. View

Lemberg K, Gori S, Tsukamoto T, Rais R, Slusher B . Clinical development of metabolic inhibitors for oncology. J Clin Invest. 2022; 132(1). PMC: 8718137. DOI: 10.1172/JCI148550. View

Nishizawa N, Shimajiri S, Oyama R, Manabe T, Nemoto Y, Matsumiya H . Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression. Sci Rep. 2023; 13(1):21687. PMC: 10709433. DOI: 10.1038/s41598-023-47888-x. View

Nicholson S, Willson T, Farley A, Starr R, Zhang J, Baca M . Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999; 18(2):375-85. PMC: 1171132. DOI: 10.1093/emboj/18.2.375. View

Mishra A, Ali A, Dutta S, Banday S, Malonia S . Emerging Trends in Immunotherapy for Cancer. Diseases. 2022; 10(3). PMC: 9498256. DOI: 10.3390/diseases10030060. View

Islas-Vazquez L, Aguilar-Cazares D, Galicia-Velasco M, Rumbo-Nava U, Meneses-Flores M, Luna-Rivero C . IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma. Biology (Basel). 2020; 9(11). PMC: 7694324. DOI: 10.3390/biology9110376. View

Kumari N, Dwarakanath B, Das A, Bhatt A . Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016; 37(9):11553-11572. DOI: 10.1007/s13277-016-5098-7. View

10.

Paolini R, Molfetta R . CD155 and Its Receptors as Targets for Cancer Therapy. Int J Mol Sci. 2023; 24(16). PMC: 10455395. DOI: 10.3390/ijms241612958. View

11.

Soriani A, Zingoni A, Cerboni C, Iannitto M, Ricciardi M, Di Gialleonardo V . ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2008; 113(15):3503-11. DOI: 10.1182/blood-2008-08-173914. View

12.

Tawara K, Oxford J, Jorcyk C . Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res. 2011; 3:177-89. PMC: 3101113. DOI: 10.2147/CMR.S18101. View

13.

Ju X, Zhang H, Zhou Z, Chen M, Wang Q . Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling. Exp Cell Res. 2020; 396(2):112315. DOI: 10.1016/j.yexcr.2020.112315. View

14.

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

15.

Chen Y, Zhou Y, Tang L, Peng X, Jiang H, Wang G . Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. J Cancer. 2019; 10(25):6261-6268. PMC: 6856743. DOI: 10.7150/jca.34677. View

16.

Wienke J, Visser L, Kholosy W, Keller K, Barisa M, Poon E . Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. Cancer Cell. 2024; 42(2):283-300.e8. PMC: 10864003. DOI: 10.1016/j.ccell.2023.12.008. View

17.

Berzaghi R, Maia V, Pereira F, Melo F, Guedes M, Origassa C . SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. Sci Rep. 2017; 7:40585. PMC: 5227698. DOI: 10.1038/srep40585. View

18.

Tobelaim W, Beaurivage C, Champagne A, Pomerleau V, Simoneau A, Chababi W . Tumour-promoting role of SOCS1 in colorectal cancer cells. Sci Rep. 2015; 5:14301. PMC: 4585755. DOI: 10.1038/srep14301. View

19.

Schaper F, Rose-John S . Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015; 26(5):475-87. DOI: 10.1016/j.cytogfr.2015.07.004. View

20.

Flowers L, Subramaniam P, Johnson H . A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene. 2005; 24(12):2114-20. DOI: 10.1038/sj.onc.1208437. View